These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
345 related articles for article (PubMed ID: 33417137)
1. Molecular diagnosis of diffuse glioma using a chip-based digital PCR system to analyze IDH, TERT, and H3 mutations in the cerebrospinal fluid. Fujioka Y; Hata N; Akagi Y; Kuga D; Hatae R; Sangatsuda Y; Michiwaki Y; Amemiya T; Takigawa K; Funakoshi Y; Sako A; Iwaki T; Iihara K; Mizoguchi M J Neurooncol; 2021 Mar; 152(1):47-54. PubMed ID: 33417137 [TBL] [Abstract][Full Text] [Related]
2. Applications of cerebrospinal fluid circulating tumor DNA in the diagnosis of gliomas. Zhao Z; Zhang C; Li M; Shen Y; Feng S; Liu J; Li F; Hou L; Chen Z; Jiang J; Ma X; Chen L; Yu X Jpn J Clin Oncol; 2020 Mar; 50(3):325-332. PubMed ID: 32039443 [TBL] [Abstract][Full Text] [Related]
3. Molecular Diagnosis of Diffuse Gliomas through Sequencing of Cell-Free Circulating Tumor DNA from Cerebrospinal Fluid. Martínez-Ricarte F; Mayor R; Martínez-Sáez E; Rubio-Pérez C; Pineda E; Cordero E; Cicuéndez M; Poca MA; López-Bigas N; Ramon Y Cajal S; Vieito M; Carles J; Tabernero J; Vivancos A; Gallego S; Graus F; Sahuquillo J; Seoane J Clin Cancer Res; 2018 Jun; 24(12):2812-2819. PubMed ID: 29615461 [No Abstract] [Full Text] [Related]
4. Detection of Histone H3 mutations in cerebrospinal fluid-derived tumor DNA from children with diffuse midline glioma. Huang TY; Piunti A; Lulla RR; Qi J; Horbinski CM; Tomita T; James CD; Shilatifard A; Saratsis AM Acta Neuropathol Commun; 2017 Apr; 5(1):28. PubMed ID: 28416018 [TBL] [Abstract][Full Text] [Related]
5. Liquid biopsy for pediatric diffuse midline glioma: a review of circulating tumor DNA and cerebrospinal fluid tumor DNA. Azad TD; Jin MC; Bernhardt LJ; Bettegowda C Neurosurg Focus; 2020 Jan; 48(1):E9. PubMed ID: 31896079 [TBL] [Abstract][Full Text] [Related]
6. Standardization of the liquid biopsy for pediatric diffuse midline glioma using ddPCR. Li D; Bonner ER; Wierzbicki K; Panditharatna E; Huang T; Lulla R; Mueller S; Koschmann C; Nazarian J; Saratsis AM Sci Rep; 2021 Mar; 11(1):5098. PubMed ID: 33658570 [TBL] [Abstract][Full Text] [Related]
7. Use of telomerase promoter mutations to mark specific molecular subsets with reciprocal clinical behavior in IDH mutant and IDH wild-type diffuse gliomas. Akyerli CB; Yüksel Ş; Can Ö; Erson-Omay EZ; Oktay Y; Coşgun E; Ülgen E; Erdemgil Y; Sav A; von Deimling A; Günel M; Yakıcıer MC; Pamir MN; Özduman K J Neurosurg; 2018 Apr; 128(4):1102-1114. PubMed ID: 28621624 [TBL] [Abstract][Full Text] [Related]
8. Muralidharan K; Yekula A; Small JL; Rosh ZS; Kang KM; Wang L; Lau S; Zhang H; Lee H; Bettegowda C; Chicoine MR; Kalkanis SN; Shankar GM; Nahed BV; Curry WT; Jones PS; Cahill DP; Balaj L; Carter BS Clin Cancer Res; 2021 Jan; 27(1):169-178. PubMed ID: 33051308 [TBL] [Abstract][Full Text] [Related]
9. IDH1 p.R132H ctDNA and D-2-hydroxyglutarate as CSF biomarkers in patients with IDH-mutant gliomas. Fujita Y; Nunez-Rubiano L; Dono A; Bellman A; Shah M; Rodriguez JC; Putluri V; Kamal AHM; Putluri N; Riascos RF; Zhu JJ; Esquenazi Y; Ballester LY J Neurooncol; 2022 Sep; 159(2):261-270. PubMed ID: 35816267 [TBL] [Abstract][Full Text] [Related]
10. Sensitive and rapid detection of TERT promoter and IDH mutations in diffuse gliomas. Diplas BH; Liu H; Yang R; Hansen LJ; Zachem AL; Zhao F; Bigner DD; McLendon RE; Jiao Y; He Y; Waitkus MS; Yan H Neuro Oncol; 2019 Mar; 21(4):440-450. PubMed ID: 30346624 [TBL] [Abstract][Full Text] [Related]
11. [The Present and Future of Less-invasive Liquid Biopsy for the Diagnosis of Gliomas and Brain Tumors]. Natsumeda M; On J; Watanabe J; Tsukamoto Y; Okada M; Fujii Y; Adachi J; Nishikawa R No Shinkei Geka; 2021 May; 49(3):527-534. PubMed ID: 34092558 [TBL] [Abstract][Full Text] [Related]
12. TERT Promoter Mutation Analysis to Distinguish Glioma From Gliosis. Hewer E; Phour J; Gutt-Will M; Schucht P; Dettmer MS; Vassella E J Neuropathol Exp Neurol; 2020 Apr; 79(4):430-436. PubMed ID: 32068851 [TBL] [Abstract][Full Text] [Related]
13. Diagnostic implications of TERT promoter mutation status in diffuse gliomas in a routine clinical setting. Hewer E; Prebil N; Berezowska S; Gutt-Will M; Schucht P; Dettmer MS; Vassella E Virchows Arch; 2017 Nov; 471(5):641-649. PubMed ID: 28823044 [TBL] [Abstract][Full Text] [Related]
14. Clinical implications of TERT promoter mutation on IDH mutation and MGMT promoter methylation in diffuse gliomas. Kim HS; Kwon MJ; Song JH; Kim ES; Kim HY; Min KW Pathol Res Pract; 2018 Jun; 214(6):881-888. PubMed ID: 29650441 [TBL] [Abstract][Full Text] [Related]
15. Electronic DNA Analysis of CSF Cell-free Tumor DNA to Quantify Multi-gene Molecular Response in Pediatric High-grade Glioma. Bruzek AK; Ravi K; Muruganand A; Wadden J; Babila CM; Cantor E; Tunkle L; Wierzbicki K; Stallard S; Dickson RP; Wolfe I; Mody R; Schwartz J; Franson A; Robertson PL; Muraszko KM; Maher CO; Garton HJL; Qin T; Koschmann C Clin Cancer Res; 2020 Dec; 26(23):6266-6276. PubMed ID: 33087334 [TBL] [Abstract][Full Text] [Related]
16. Clinically Relevant and Minimally Invasive Tumor Surveillance of Pediatric Diffuse Midline Gliomas Using Patient-Derived Liquid Biopsy. Panditharatna E; Kilburn LB; Aboian MS; Kambhampati M; Gordish-Dressman H; Magge SN; Gupta N; Myseros JS; Hwang EI; Kline C; Crawford JR; Warren KE; Cha S; Liang WS; Berens ME; Packer RJ; Resnick AC; Prados M; Mueller S; Nazarian J Clin Cancer Res; 2018 Dec; 24(23):5850-5859. PubMed ID: 30322880 [TBL] [Abstract][Full Text] [Related]
17. IDH1 mutation detection by droplet digital PCR in glioma. Wang J; Zhao YY; Li JF; Guo CC; Chen FR; Su HK; Zhao HF; Long YK; Shao JY; To Ss; Chen ZP Oncotarget; 2015 Nov; 6(37):39651-60. PubMed ID: 26485760 [TBL] [Abstract][Full Text] [Related]
18. Molecular profiling of tumors of the brainstem by sequencing of CSF-derived circulating tumor DNA. Pan C; Diplas BH; Chen X; Wu Y; Xiao X; Jiang L; Geng Y; Xu C; Sun Y; Zhang P; Wu W; Wang Y; Wu Z; Zhang J; Jiao Y; Yan H; Zhang L Acta Neuropathol; 2019 Feb; 137(2):297-306. PubMed ID: 30460397 [TBL] [Abstract][Full Text] [Related]
19. PI3 kinase mutations and mutational load as poor prognostic markers in diffuse glioma patients. Draaisma K; Wijnenga MM; Weenink B; Gao Y; Smid M; Robe P; van den Bent MJ; French PJ Acta Neuropathol Commun; 2015 Dec; 3():88. PubMed ID: 26699864 [TBL] [Abstract][Full Text] [Related]
20. Liquid Biopsy of Cerebrospinal Fluid Enables Selective Profiling of Glioma Molecular Subtypes at First Clinical Presentation. Orzan F; De Bacco F; Lazzarini E; Crisafulli G; Gasparini A; Dipasquale A; Barault L; Macagno M; Persico P; Pessina F; Bono B; Giordano L; Zeppa P; Melcarne A; Cassoni P; Garbossa D; Santoro A; Comoglio PM; Indraccolo S; Simonelli M; Boccaccio C Clin Cancer Res; 2023 Apr; 29(7):1252-1266. PubMed ID: 36648487 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]